BACKGROUND: This study was conducted to measure the serial changes in pulmonary function over 12 months after lobectomy in subjects with lung cancer and to evaluate the actual recovery of pulmonary function in comparison with the predicted postoperative values. METHODS: Subjects who underwent lobectomy for primary lung cancer were included in this study. In the statistical analysis, we included data from 76 subjects (52 men and 24 women; mean age, 63.4 y) who completed perfusion scintigraphy 1 week before surgery and FEV 1 and diffusion capacity of the lung for carbon monoxide (D LCO ) assessments preoperatively and at 1, 6, and 12 months postoperatively. RESULTS: The actual percent-of-predicted FEV 1 1 month postoperatively was 77.9% of the preoperative value, which was almost equal to the predicted postoperative value, and significantly increased to 84.3% by 6 months and 84.2% at 12 months. The actual percent-of-predicted D LCO 1 month postoperatively was 81.8% of the preoperative value, which was similar to the predicted postoperative value, and also significantly increased to 91.3% at 6 months and 96.5% at 12 months. However, the actual pulmonary function test results at 1 y in subjects with COPD or in those who underwent thoracotomy or received adjuvant chemotherapy were not different from the predicted postoperative values. CONCLUSIONS: Actual pulmonary function compared with predicted postoperative values improved over time over 1 y after lobectomy. However, this improvement was not observed in subjects with COPD or in those who underwent thoracotomy or received postoperative adjuvant chemotherapy.
Introduction
Lung cancer is one of the most common malignancies and is one of the leading causes of death worldwide. 1 Surgical resection has been regarded as the best treatment for controlling stage I, stage II, and part of stage III A non-small-cell lung cancer. However, in some subjects with early stage non-small-cell lung cancer, poor respiratory function may interfere with surgery because of the increased risk for perioperative morbidity and mortality and the possibility of long-term postoperative disability secondary to respiratory insufficiency. 2 Baser et al 3 reported that 37% of subjects who had anatomically resectable lung cancers were excluded from surgical resection only because of poor lung function. Therefore, predicting postoperative pulmonary function, particularly FEV 1 and the diffusion capacity of the lung for carbon monoxide (D LCO ), plays an important role in determining candidates for surgical resection and the extent of resection. 4 A number of related studies have been conducted to predict pulmonary function after surgery. 5 However, reaching a definitive conclusion about predicting postoperative pulmonary function was difficult in most of these studies because they were based on small samples and short monitoring periods (3 or 6 months at the longest). [6] [7] [8] Furthermore, surgical techniques and postoperative care have steadily improved since these studies were performed.
Recently, the authors showed that actual pulmonary function results at approximately 1 month after surgery were similar to predicted postoperative pulmonary function values. 9 In addition, Brunelli et al 10 performed a prospective study of a large sample (Ͼ200 subjects) and found that actual postoperative lung function reached predicted postoperative values at 1 month after surgery and showed further improvement at 3 months after surgery. Based on these studies, we aimed to evaluate whether pulmonary function would continue to improve during the long-term follow-up after operation, and in the present study, we monitored the changes in actual postoperative lung function over 1 y after lobectomy in subjects with lung cancer and evaluated the degree of actual recovery compared with predicted postoperative values. In addition, we analyzed differences in the results according to factors including the presence or absence of COPD, surgical method (video-assisted thoracoscopic surgery [VATS] vs thoracotomy), and the use of adjuvant chemotherapy after operation.
Methods
Subjects who underwent lobectomy for primary lung cancer from April 2009 through January 2012 at Korea University Guro Hospital were included in this study. Subject data were prospectively collected and were analyzed. Exclusionary criteria included cancer with chest wall invasion, endobronchial cancer with post-obstructive pneumonitis, and subjects who underwent neoadjuvant chemotherapy. Patients who had any major complications or required ventilatory support that interfered with assessment of pulmonary function in the postoperative period were also excluded. This study was approved by the Ethics Committee of Korea University Guro Hospital (KUGH 2014-01-0004), and written informed consent was obtained from all subjects, in accordance with the Declaration of Helsinki.
Subjects underwent pulmonary function tests and perfusion scintigraphy within 1 week before surgery and postoperative pulmonary function tests at 1, 6, and 12 months after surgery. The pulmonary function tests were performed according to the published guidelines using a spirometer (Vmax22, SensorMedics, Yorba Linda, California). 11 The D LCO was measured using the single-breath method. Spirometry and D LCO results were collected after bronchodilator administration and are expressed as percentages of age, sex, and height of the subject according to the European Community for Steel and Coal prediction equations. 12 The preoperative radionuclide quantitative lung perfusion scans were performed in all subjects with an Infinia multidetector system (GE Medical Systems, Haifa, Israel) to estimate the predicted postoperative values, as described by Ali, 13 , which was our routine procedure until January 2009: (1) postoperative percent-of-predicted FEV 1 ϭ preoperative percent-of-predicted FEV 1 ϫ (100% Ϫ projected percentage loss of lung function) and (2) postoperative percent-of-predicted D LCO ϭ preoperative percent-of-predicted D LCO ϫ (100% Ϫ projected percentage loss of lung function).
Statistics
The descriptive statistics of FEV 1 and D LCO measurements are presented as the mean and SD. We used paired and independent t tests to compare groups with normally distributed data and the Wilcoxon signed-rank test and Mann-Whitney test for non-normal data. Data analysis was performed with SPSS 20 (SPSS, Chicago, Illinois).
Results
A total of 76 subjects (52 men and 24 women) who completed FEV 1 and D LCO assessments preoperatively and at 1, 6, and 12 months postoperatively were included in the statistical analysis.
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Current knowledge
Lung cancer is one of the most common malignancies and a leading cause of death worldwide. Surgical resection is the standard of care in non-small-cell lung cancer. Poor respiratory function may preclude surgery in select patients due to the increased risk for perioperative morbidity and mortality. Long-term postoperative disability secondary to respiratory failure represents a significant cost burden.
What this paper contributes to our knowledge
Actual pulmonary function compared with predicted postoperative values improved 1 y after lobectomy. This improvement was not observed in subjects with COPD, in those who underwent thoracotomy, or those who received postoperative adjuvant chemotherapy.
The characteristics of these subjects are shown in Table  1 . The mean age of the subjects was 63.4 Ϯ 8.98 y (range, 43-80 y). The average FEV 1 /FVC ratio was 0.72 Ϯ 0.10. Seven subjects (9.2%) had COPD, 46 (60.5%) underwent resection via VATS, and 22 (29%) received adjuvant chemotherapy after surgery. The pathology was adenocarcinoma in 38 subjects (50%), squamous cell carcinoma in 30 subjects (39.5%), and other in 8 subjects (10.5%). At clinical staging, all subjects appeared node-negative; the pathologic stages were N0 in 62 subjects, N1 in 7, and N2 in 7.
Preoperative and predicted and actual postoperative values at each time point in subjects with complete follow-up data are shown in Table 2 and Figure 1 . At 1, 6, and 12 months after operation, actual percent-of-predicted FEV 1 values were 77.9, 84.3, and 84.2%, respectively, of the preoperative values. The actual percent-of-predicted FEV 1 was almost equal to the predicted postoperative value at 1 month and increased at 6 months (P ϭ .03) but showed no further increase at 12 months. Actual postoperative percent-of-predicted D LCO values were 81.8, 91.3, and 96.5% of the preoperative values at 1, 6, and 12 months, respectively. The actual percent-of-predicted D LCO was similar to the predicted postoperative value at 1 month and increased at 6 months (P ϭ .01). Compared with the percent-of-predicted FEV 1 , the actual percent-of-predicted D LCO showed a greater increase and approximated the preoperative value at 1 y after operation. Figure 2 shows the comparative pulmonary function data according to the presence (7 subjects) or absence (69 subjects) of COPD. Significant improvements were observed in percent-of-predicted FEV 1 (P ϭ .02) and percent-of-predicted D LCO (P Ͻ .01) between 1 and 6 months after operation in non-COPD subjects. However, no significant recovery of pulmonary function was observed over the entire period in those with COPD. Significant differences in preoperative and predicted postoperative percentof-predicted FEV 1 values between the 2 groups did not reduce during the 1-y follow-up after operation. On the other hand, from 6 months after operation, the actual percent-of-predicted D LCO showed a dramatic improvement in non-COPD subjects compared with those with COPD. Figure 3 shows comparative pulmonary function data according to the type of surgery (VATS in 46 subjects vs thoracotomy in 30). Significant improvements were observed in percent-of-predicted FEV 1 (P ϭ .02) and percent-of-predicted D LCO (P ϭ .01) between 1 and 6 months after operation in subjects who underwent VATS. However, no significant improvement was observed over the entire period in the thoracotomy group. From 6 months after operation, the actual percent-of-predicted FEV 1 showed significant improvement after VATS versus thoracotomy, although the actual percent-of-predicted D LCO showed no difference between the 2 groups during the 1-y follow-up after operation. Figure 4 shows the comparative pulmonary function data between subjects receiving adjuvant chemotherapy (22 subjects) or not (54 subjects). Significant improvements were observed in percent-of-predicted FEV 1 (P ϭ .02) and percent-of-predicted D LCO (P ϭ .02) between 1 and 6 months after operation in the nonadjuvant group. However, no significant improvement was observed over the entire period in the adjuvant group. From 6 months after operation, the actual percent-of-predicted FEV 1 showed significant improvement in the non-adjuvant group compared with the adjuvant group, and the actual percent-of-predicted D LCO showed significant improvement in the non-adjuvant group compared with the adjuvant group at 1 y after operation. The actual postoperative percent-of-predicted D LCO values at 6 and 12 months were significantly higher in subjects without COPD than in those with COPD (f, P Ͻ .001; g, P Ͻ .001). 
Discussion
Predicted postoperative pulmonary function in patients undergoing major pulmonary resection for lung cancer plays an important role in determining operability and predicting quality of life after surgery. In particular, FEV 1 and D LCO are useful predictors of postoperative mortality and complications. 14, 15 In a previous study, 9 we showed that predicted postoperative pulmonary function was similar to the actual postoperative value at 1 month after surgery, and Brunelli et al 10 demonstrated that actual postoperative lung function improved to an even greater extent at 3 months after surgery. Based on these findings, we wanted to know how much and for how long pulmonary function would continue to be recovered after major pulmonary resection in lung cancer patients.
In the present study, we found that actual percent-ofpredicted FEV 1 was similar to the predicted value at 1 month after surgery, significantly increased to 1.11 times the predicted postoperative value at 6 months after surgery, and remained at approximately the same level (84.0% of the preoperative value) until 12 months after surgery. The actual percent-of-predicted D LCO was not different from the predicted value at 1 month after surgery but significantly increased to 1.19 times the predicted postoperative value at 6 months and eventually reached 1.26 times the predicted postoperative value by 12 months (97.2% of the preoperative value). These results indicate that the postoperative percent-of-predicted D LCO exhibits greater recovery compared with FEV 1 , which is similar to the findings reported by Brunelli et al. 10 This finding may be explained by pulmonary vascular and hemodynamic compensatory mechanisms. 16 Several authors have reported that the percent-of-predicted FEV 1 in COPD subjects was decreased to a lesser extent or even improved after surgical resection compared with the percent-of-predicted FEV 1 in non-COPD subjects, [17] [18] [19] and the difference was more prominent at the early phase (1-3 months) after surgery. 10, 20 This might be attributed to the similar effect of lung volume reduction surgery for subjects with bullous emphysema. Further, it has also been noted that the actual postoperative percentof-predicted D LCO in subjects with COPD shows a marked increase with improvement of the ventilation/perfusion ratio. [17] [18] [19] In the present study, the actual percent-of-predicted FEV 1 had a tendency to exceed the predicted postoperative value in subjects with COPD (1.13 times the predicted postoperative value) at 1 month after surgery (P ϭ .06), but these values did not increase thereafter; meanwhile, the actual percent-of-predicted D LCO in COPD subjects showed no improvement, reaching only 73.5% of the preoperative value (1.05 times the predicted postoperative value) at 1 y after surgery. This inconsistency with the previous results may be due to the small number of COPD subjects (n ϭ 7) in our study. On the other hand, the actual percent-of-predicted FEV 1 in the non-COPD group was similar to the predicted postoperative value (1.01 times the predicted postoperative value) at 1 month after surgery, significantly increased to 1.11 times the predicted postoperative value at 6 months, and remained at approximately the same level at 12 months (85.1% of the preoperative value). The actual percent-of-predicted D LCO VATS is associated with faster recovery of pulmonary function after surgery because of its reduced invasiveness, which reduces postoperative pain, impairment of respiratory muscles, and damage to the thoracic wall. [21] [22] [23] [24] [25] In the present study, the recovery of actual pulmonary function after VATS was not different from that after thoracotomy at 1 month after operation. However, the actual percentof-predicted FEV 1 in the VATS group significantly increased at 6 months after operation to 1.14 times the predicted postoperative value and eventually reached 89.0% of the preoperative value at 12 months (1.20 times the predicted postoperative value), whereas it did not increase significantly in the thoracotomy group. Although there were no significant differences overall in the percent-ofpredicted D LCO values between the 2 groups, the actual percent-of-predicted D LCO in the VATS group had recovered significantly to 91.8% of the preoperative value (1.22 times the predicted postoperative value) at 6 months and continued to increase to 99.2% of the preoperative value (1.32 times the predicted postoperative value) at 12 months, whereas there was no significant improvement of the actual percent-of-predicted D LCO observed in the thoracotomy subjects (82.2% of the preoperative value at 1 month to 89.1% at 12 months).
Adjuvant chemotherapeutic agents for non-small-cell lung cancer are known to have various adverse effects, including dyspnea, cough, wheezing, chest tightness, and hypersensitivity reaction. 14, 26, 27 Approximately 10% of subjects who receive chemotherapy exhibit pulmonary toxicity, which mainly manifests as a parenchymal lung injury, such as pneumonitis or interstitial lung disease. 14, 15, 26, 28, 29 This toxicity might present as airway or pleural disease or in various other ways. 15, 29 Therefore, adjuvant chemotherapy after major lung resection can affect the recovery of pulmonary function. In the present study, the actual percent-of-predicted FEV 1 significantly increased to 85.9% of the preoperative value (1.11 times the predicted postoperative value) at 12 months in subjects who did not receive adjuvant chemotherapy, whereas the increase was not significant in the adjuvant group (79.0% of the preoperative value at 1 month to 81.9% at 12 months). The actual percent-of-predicted D LCO in the non-adjuvant group showed a marked recovery to 98.4% of the preoperative value (1.29 times the predicted postoperative value) at 12 months, whereas no significant improvement of the actual percent-of-predicted D LCO was observed in the adjuvant group (79.6% at 1 month to 83.9% at 12 months). This result demonstrates the negative effect of adjuvant chemotherapy on pulmonary function recovery after operation and is compatible with the findings of previous studies. This study had limitations, including the small number of subjects and the uneven distribution for subgroup analysis, especially for the presence of COPD.
Conclusions
In conclusion, the actual pulmonary function after surgery improved above the level of the predicted postoperative values for 1 y. The postoperative predicted values are an underestimate of the actual lung function recovery over a period of 1 y. This has clinical implications because this underestimation may lead to curative resection being withheld in marginal candidates. Therefore, the systematic use of exercise testing should be considered. 16 However, this improvement was not observed in subjects with COPD, subjects who underwent thoracotomy, or those who received postoperative adjuvant chemotherapy. The result of this study should be useful for the determination of surgical candidates, of the extent of resection, and of the strategy of postoperative pulmonary care.
